In gastric cancer patients treated by first-line combinational therapy with epirubicin, oxaliplatin, and 5-fluorouracil, IGF2BP2 polymorphisms rs4402960 and rs6769511 are less common in patients with disease progression than in those with controlled disease [28]. The gene discussed is IGF2BP2; the disease is gastric cancer.